Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): cancer concerns.
作者信息
Wooltorton Eric
出版信息
CMAJ. 2005 Apr 26;172(9):1179-80. doi: 10.1503/cmaj.050373. Epub 2005 Apr 7.
Abstract
摘要
相似文献
1
Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): cancer concerns.湿疹药物他克莫司（普特彼）和吡美莫司（爱宁达）：癌症相关问题。
CMAJ. 2005 Apr 26;172(9):1179-80. doi: 10.1503/cmaj.050373. Epub 2005 Apr 7.
2
[Creams used in the treatment of children can cause cancer].用于治疗儿童的乳膏可能致癌。
Ugeskr Laeger. 2005 Mar 21;167(12-13):1415-7.
3
[Topical immunomodulators, such as tacrolimus and pimecrolimus, in the treatment of atopic dermatitis].[外用免疫调节剂，如他克莫司和吡美莫司，用于治疗特应性皮炎]
Ned Tijdschr Geneeskd. 2005 Aug 6;149(32):1816; author reply 1817.
4
FDA warns about Elidel, Protopic.美国食品药品监督管理局就爱宁达、普特彼发出警告。
Child Health Alert. 2005 May;23:6.
5
[Therapy of atopic eczema with calcineurin inhibitors].[用钙调神经磷酸酶抑制剂治疗特应性皮炎]
J Dtsch Dermatol Ges. 2005 May;3(5):385-91.
6
[No increased risk of cancer under pimecrolimus].[吡美莫司治疗下无癌症风险增加]
Ann Dermatol Venereol. 2016 Jan;143(1):98-9. doi: 10.1016/j.annder.2015.11.003. Epub 2015 Dec 18.
7
Association between exposure to topical tacrolimus or pimecrolimus and cancers.局部使用他克莫司或吡美莫司与癌症的关联性。
Ann Pharmacother. 2009 Dec;43(12):1956-63. doi: 10.1345/aph.1M278. Epub 2009 Nov 10.
8
[Topical immunomodulators, such as tacrolimus and pimecrolimus, in the treatment of atopic dermatitis].[外用免疫调节剂，如他克莫司和吡美莫司，用于治疗特应性皮炎]
Ned Tijdschr Geneeskd. 2005 May 14;149(20):1096-100.
9
[Tacrolimus and pimecrolimus ointments in the treatment of atopic eczema].[他克莫司和吡美莫司软膏治疗特应性皮炎]
Duodecim. 2003;119(9):825-7.
10
The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update.外用钙调神经磷酸酶抑制剂吡美莫司治疗特应性皮炎：安全性最新进展
Acta Dermatovenerol Alp Pannonica Adriat. 2007 Jun;16(2):58, 60-62.
引用本文的文献
1
Efficacy and Safety of Topical Tacrolimus in Comparison with Topical Corticosteroids, Calcineurin Inhibitors, Retinoids and Placebo in Oral Lichen Planus: An Updated Systematic Review and Meta-Analysis.局部他克莫司与局部皮质类固醇、钙调磷酸酶抑制剂、维 A 酸和安慰剂治疗口腔扁平苔藓的疗效和安全性：更新的系统评价和荟萃分析。
Asian Pac J Cancer Prev. 2023 Feb 1;24(2):389-400. doi: 10.31557/APJCP.2023.24.2.389.
2
Functional interpretation of metabolomics data as a new method for predicting long-term side effects: treatment of atopic dermatitis in infants.代谢组学数据的功能解释作为预测长期副作用的新方法：婴儿特应性皮炎的治疗
Sci Rep. 2014 Dec 10;4:7408. doi: 10.1038/srep07408.
3
Photocarcinogenicity of selected topically applied dermatological drugs: calcineurin inhibitors, corticosteroids, and vitamin D analogs.部分局部应用皮肤科药物的光致癌性：钙调神经磷酸酶抑制剂、皮质类固醇和维生素D类似物。
Dermatol Reports. 2010 Sep 14;2(2):e13. doi: 10.4081/dr.2010.e13. eCollection 2010 Aug 31.
4
Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus.外用钙调神经磷酸酶抑制剂在皮肤型红斑狼疮中的应用进展
Biologics. 2011;5:21-31. doi: 10.2147/BTT.S9806. Epub 2011 Feb 14.
5
Topical calcineurin inhibitors in systemic lupus erythematosus.局部钙调磷酸酶抑制剂治疗系统性红斑狼疮。
Ther Clin Risk Manag. 2010 Apr 15;6:95-101. doi: 10.2147/tcrm.s3193.
6
Questions and answers on immunization.免疫接种问答
Paediatr Child Health. 2006 Feb;11(2):110.
本文引用的文献
1
Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.外用吡美莫司和他克莫司治疗特应性皮炎的疗效及耐受性：随机对照试验的荟萃分析
BMJ. 2005 Mar 5;330(7490):516. doi: 10.1136/bmj.38376.439653.D3. Epub 2005 Feb 24.
2
Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin.免疫抑制剂他克莫司的局部应用会加速小鼠皮肤的癌变。
Br J Dermatol. 2003 Nov;149(5):960-7. doi: 10.1111/j.1365-2133.2003.05735.x.
Zotero 插件